Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 1, pp 147–156

Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis

  • Kurt Van der Speeten
  • O. Anthony Stuart
  • David Chang
  • Haile Mahteme
  • Paul H. Sugarbaker
Original Article



Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are a combined treatment modality considered for selected patients with peritoneal carcinomatosis from colorectal and appendiceal cancer. Mitomycin C is a drug often used in this clinical setting. The surgical and clinical factors that may influence the pharmacokinetics of hyperthermic intraperitoneal chemotherapy should be further elucidated.

Materials and methods

The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen. The effect of clinical and surgical factors on drug distribution after single intraperitoneal bolus administration with mitomycin C was determined.


The pharmacokinetics of 145 patients treated with intraperitoneal mitomycin C showed a 27 times greater exposure to peritoneal surfaces when compared to plasma. At 90 min, 29% of the drug remained in the chemotherapy solution, 62% was retained in the body, and 9% was excreted in the urine. The extent of peritonectomy increased the clearance of mitomycin C from the peritoneal space (p = 0.051). A major resection of visceral peritoneal surface and a contracted peritoneal space reduced drug clearance. A contracted peritoneal space significantly reduced (p = 0.0001) drug concentrations in the plasma.


Surgical and clinical factors may require modifications of drug dose or timing of chemotherapy administration. A large visceral resection and a contracted peritoneal space caused a reduced mitomycin C clearance. Total diffusion surface is an important determinant of mitomycin C pharmacokinetics.


Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy (HIPEC) Mitomycin C Intraperitoneal chemotherapy Appendix cancer Colorectal cancer Chemotherapy pharmacokinetics 


  1. 1.
    Verwaal VJ, Bruin S, Boot H, Van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–2432PubMedCrossRefGoogle Scholar
  2. 2.
    Sugarbaker PH (2009) Epithelial appendiceal neoplasms. Cancer J 15:225–235PubMedCrossRefGoogle Scholar
  3. 3.
    Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC (1981) Enhancement by hyperthermia of the in vitro cytotoxicity of Mitomycin C toward hypoxic tumor cells. Cancer Res 41:1096–1099PubMedGoogle Scholar
  4. 4.
    Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermo chemotherapy given at mild temperatures. Int J Hyperthermia 15:79–107PubMedCrossRefGoogle Scholar
  5. 5.
    Link KH, Leder G, Pillasch J, Butzer U, Staib L, Kornmann M, Bruckner U, Beger HG (1998) In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol 14:189–201PubMedCrossRefGoogle Scholar
  6. 6.
    Fujita T, Tamura T, Yamada H, Yamamoto A, Muranishi S (1997) Pharmacokinetics of mytomycin C(MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. J Drug Target 4:289–296PubMedCrossRefGoogle Scholar
  7. 7.
    Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40:1165–1168PubMedGoogle Scholar
  8. 8.
    Gilly FN, Carry PY, Sayag AC, Panteix G, Manchon M, Rochette A, Peix JL, Baulieux J, James I, Braillon G (1992) Tolerance of intraperitoneal chemohyperthermia with mitomycin C: in vivo study in dogs. Int J Hyperthermia 8:659–666PubMedCrossRefGoogle Scholar
  9. 9.
    Murphy EM, Sexton R, Moran BJ (2007) Early results of surgery in 123 patients with pseudomyxoma peritonei from perforated appendiceal neoplasm. Dis Colon Rectum 50:37–42PubMedCrossRefGoogle Scholar
  10. 10.
    Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20:61–69PubMedCrossRefGoogle Scholar
  11. 11.
    Scaringi S, Kianmanesh R, Sabate JM, Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y, Msika S (2008) Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol 34:1246–1252PubMedGoogle Scholar
  12. 12.
    Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M (2009) Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 16:463–472PubMedCrossRefGoogle Scholar
  13. 13.
    Sugarbaker PH (1999) Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 43(Suppl):S15–S25PubMedCrossRefGoogle Scholar
  14. 14.
    Esquivel J (2009) Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea. Cancer J 15:249–254PubMedCrossRefGoogle Scholar
  15. 15.
    Van Ruth S, Verwaal VJ, Zoetmulder FAN (2003) Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 12:771–780PubMedCrossRefGoogle Scholar
  16. 16.
    Elias DM, Sideris L (2003) Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 12:755–769PubMedCrossRefGoogle Scholar
  17. 17.
    Sugarbaker PH, Stuart OA, Carmignani CP (2006) Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 57:703–708PubMedCrossRefGoogle Scholar
  18. 18.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42PubMedCrossRefGoogle Scholar
  19. 19.
    De Lima Vazquez V, Sugarbaker PH (2003) Total anterior parietal peritonectomy. J Surg Oncol 83:261–263CrossRefGoogle Scholar
  20. 20.
    De Lima Vazquez V, Sugarbaker PH (2003) Cholecystectomy, lesser omentectomy and stripping of the omental bursa, a peritonectomy procedure. J Surg Oncol 84:45–49CrossRefGoogle Scholar
  21. 21.
    Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267–272PubMedCrossRefGoogle Scholar
  22. 22.
    Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58Google Scholar
  23. 23.
    Dalton JT, Geuns ER, Au JL (1989) High performance liquid chromatography determination of mitomycin C in rat and human plasma and urine. J Chromatogr Biomed Appl 495:330–337CrossRefGoogle Scholar
  24. 24.
    Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH (1998) Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies. Oncology 55:130–138PubMedCrossRefGoogle Scholar
  25. 25.
    Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL (1991) Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51:4347–4354PubMedGoogle Scholar
  26. 26.
    Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, Garbit F, Grandclément E, Vignal J, Gilly FN (2000) Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88:2512–2519PubMedCrossRefGoogle Scholar
  27. 27.
    Loggie BW, Fleming RA (1996) Complications of heated intraperitoneal chemotherapy and strategies for prevention. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwer Academic Publishers, Boston, pp 221–233Google Scholar
  28. 28.
    Fernandez-Trigo V, Stuart OA, Stephens AD, Hoover LD, Sugarbaker PH (1996) Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. Cancer Treat Res 81:51–61PubMedGoogle Scholar
  29. 29.
    Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1998) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237CrossRefGoogle Scholar
  30. 30.
    Fujimoto S, Shrestha RD, Kokobun M, Kobayashi K, Kiuchi S, Konno C, Koike S, Okui K (1989) Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg Cancer Treat 2:198–202Google Scholar
  31. 31.
    Panteix G, Guillaumont M, Cherpin L, Cuichard J, Gilly FN, Carry PY, Sayag A, Salle B, Brachet A, Bienvenu J (1993) Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology 50:366–370PubMedCrossRefGoogle Scholar
  32. 32.
    Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, Bartlett DL (2001) Laparoscopic continuous hyperthermic peritoneal perfusion. J Am Coll Surg 193:225–229PubMedCrossRefGoogle Scholar
  33. 33.
    De Lima Vazquez V, Stuart OA, Sugarbaker PH (2003) Extent of a parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol 52:108–112PubMedCrossRefGoogle Scholar
  34. 34.
    Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M (2004) Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15:1558–1565PubMedCrossRefGoogle Scholar
  35. 35.
    Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3 Suppl 4):1–6PubMedGoogle Scholar
  36. 36.
    Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG (1985) A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol 248:F425–F435PubMedGoogle Scholar
  37. 37.
    Flessner MF (2005) The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 288:433–442CrossRefGoogle Scholar
  38. 38.
    Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D (2008) Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol 15:339–344PubMedCrossRefGoogle Scholar
  39. 39.
    Thomas F, Ferron G, Gesson-Paute A, Hristova M, Lochon I, Chatelut E (2008) Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 15:3623–3624PubMedCrossRefGoogle Scholar
  40. 40.
    Khatri VP (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a panacea or just an obstacle course for the patient? J Clin Oncol 28:5–7PubMedCrossRefGoogle Scholar
  41. 41.
    Bachur NR, Gordon SL, Gee MV, Kon H (1979) NADPH cytochrome P-450 reductase activation of quinine anticancer agents to free radicals. Proc Natl Acad Sci USA 2:954–957CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Kurt Van der Speeten
    • 1
  • O. Anthony Stuart
    • 2
  • David Chang
    • 3
  • Haile Mahteme
    • 4
  • Paul H. Sugarbaker
    • 2
  1. 1.Department of Surgical OncologyZiekenhuis Oost-LimburgGenkBelgium
  2. 2.Washington Cancer InstituteWashington Hospital CenterWashingtonUSA
  3. 3.WestatRockvilleUSA
  4. 4.Department of Surgical SciencesAkademiska SjukhusetUppsalaSweden

Personalised recommendations